Phenotypic instability of Saos-2 cells in long-term culture

Hausser, Heinz; Brenner, Rolf E.

doi:10.1016/j.bbrc.2005.05.097

Cited by 130 publications

(98 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the Saos-2 cell line is advantageous because of its phenotype stability during multiple passages. 41 Saos-2 cells were stimulated to produce collagenous ECM with the addition of AA to the growth medium. Other commonly applied osteogenic additives, namely dexamethasone and β-glycerolphosphate, were shown to be toxic for Saos-2 cells (β-glycerolphosphate 42 ) or to decrease collagen deposition (dexamethasone 43 ).…”

Section: Discussionmentioning

confidence: 99%

Osteogenic cell differentiation on H-terminated and O-terminated nanocrystalline diamond films

Lišková¹,

Babchenko²,

Varga³

et al. 2015

IJN

View full text Add to dashboard Cite

Nanocrystalline diamond (NCD) films are promising materials for bone implant coatings because of their biocompatibility, chemical resistance, and mechanical hardness. Moreover, NCD wettability can be tailored by grafting specific atoms. The NCD films used in this study were grown on silicon substrates by microwave plasma-enhanced chemical vapor deposition and grafted by hydrogen atoms (H-termination) or oxygen atoms (O-termination). Human osteoblast-like Saos-2 cells were used for biological studies on H-terminated and O-terminated NCD films. The adhesion, growth, and subsequent differentiation of the osteoblasts on NCD films were examined, and the extracellular matrix production and composition were quantified. The osteoblasts that had been cultivated on the O-terminated NCD films exhibited a higher growth rate than those grown on the H-terminated NCD films. The mature collagen fibers were detected in Saos-2 cells on both the H-terminated and O-terminated NCD films; however, the quantity of total collagen in the extracellular matrix was higher on the O-terminated NCD films, as were the amounts of calcium deposition and alkaline phosphatase activity. Nevertheless, the expression of genes for osteogenic markers – type I collagen, alkaline phosphatase, and osteocalcin – was either comparable on the H-terminated and O-terminated films or even lower on the O-terminated films. In conclusion, the higher wettability of the O-terminated NCD films is promising for adhesion and growth of osteoblasts. In addition, the O-terminated surface also seems to support the deposition of extracellular matrix proteins and extracellular matrix mineralization, and this is promising for better osteoconductivity of potential bone implant coatings.

show abstract

Section: Discussionmentioning

confidence: 99%

Osteogenic cell differentiation on H-terminated and O-terminated nanocrystalline diamond films

Lišková¹,

Babchenko²,

Varga³

et al. 2015

IJN

View full text Add to dashboard Cite

show abstract

“…Whist readily available and easy to use, these models have been shown to be poorly predictive of clinical efficacy (5). By definition such lines have been selected for their ability to survive on 2D plastic surfaces and are known to drift in phenotype (6). Xenografts of such lines typically form rapidly growing, undifferentiated tumors, lacking the architecture and biological phenotype of the tumors that they are meant to represent.…”

Section: Introductionmentioning

confidence: 99%

3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors

Onion

Argent

Reece-Smith

et al. 2016

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

There is a growing recognition that current preclinical models do not reflect the tumor microenvironment in cellular, biological, and biophysical content and this may have a profound effect on drug efficacy testing, especially in the era of molecular-targeted agents. Here, we describe a method to directly embed low-passage patient tumor-derived tissue into basement membrane extract, ensuring a low proportion of cell death to anoikis and growth complementation by coculture with patient-derived cancer-associated fibroblasts (CAF). A range of solid tumors proved amenable to growth and pharmacologic testing in this 3D assay. A study of 30 early-stage non-small cell lung cancer (NSCLC) specimens revealed high levels of de novo resistance to a large range of standard-of-care agents, while histone deacetylase (HDAC) inhibitors and their combination with antineoplastic drugs displayed high levels of efficacy. Increased resistance was seen in the presence of patient-derived CAFs for many agents, highlighting the utility of the assay for tumor microenvironment-educated drug testing. Standard-of-care agents showed similar responses in the 3D ex vivo and patient-matched in vivo models validating the 3D-Tumor Growth Assay (3D-TGA) as a high-throughput screen for close-to-patient tumors using significantly reduced animal numbers. Mol Cancer Ther; 15(4); 753-63. Ó2016 AACR.

show abstract

“…Conventional drug development based on in vitro screens followed by limited in vivo testing in cell linederived tumors (25,26) poorly predicts clinical efficacy because cell lines become homogeneous and are no longer dependent on epithelial-stromal interactions responsible for in vivo oncogenesis (27)(28)(29). In the direct patient tumor models, surgical samples are implanted into immunodeficient mice, thus preserving key features that cells in culture irreversibly lose (30).…”

Section: Discussionmentioning

confidence: 99%

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

Wee

Messersmith

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Rigosertib, a dual non-ATP inhibitor of polo-like kinase 1 (Plk1) and phosphoinositide 3-kinase pathways (PI3K), and gemcitabine have synergistic antitumor activity when combined in preclinical studies. This phase I study aimed to determine the recommended phase II dose (RPTD) of the combination of rigosertib and gemcitabine in patients with cancer.Experimental Design: Patients with solid tumors who failed standard therapy or were candidates for gemcitabine-based therapy were eligible. Gemcitabine was administered on days 1, 8, and 15 on a 28-day cycle and rigosertib on days 1, 4, 8, 11, 15, and 18. Pharmacokinetic studies were conducted during an expansion cohort of patients with advanced pancreatic ductal adenocarcinoma (PDA).Results: Forty patients were treated, 19 in the dose-escalation phase and 21 in the expansion cohort. Dose levels evaluated were (gemcitabine/rigosertib mg/m 2

show abstract

Phenotypic instability of Saos-2 cells in long-term culture

Cited by 130 publications

References 24 publications

Osteogenic cell differentiation on H-terminated and O-terminated nanocrystalline diamond films

Osteogenic cell differentiation on H-terminated and O-terminated nanocrystalline diamond films

3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

Contact Info

Product

Resources

About